RxDoctor Payments Data

Krishona Poignard

Family · Cincinnati, OHNPI 1912448689

Payments from drug & device makers

$1,645in general payments, 2019–2025

Across 40 payments — averaging $41.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$378
  • Otsuka America Pharmaceutical, Inc.$361
  • Alkermes, Inc.$201
  • Axsome Therapeutics, Inc.$186
  • Lilly USA, LLC$122
  • Biohaven Pharmaceuticals, Inc.$120
  • plus $277 from 6 others

What the payments were for

  • Food & beverage$1,645100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,645 in reported general payments places this provider in the 80th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$6,983
Medicare patients
17
Services billed
70

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate47$139,888
Risperdal ConstaRisperidone Microspheres24$59,521
CaplytaLumateperone Tosylate11$17,890
SuboxoneBuprenorphine Hcl/Naloxone Hcl25$9,043
Aripiprazole80$5,654
Chlorpromazine Hcl16$5,600
Clozapine27$3,889
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl27$2,471
Lurasidone Hcl18$2,313
Olanzapine41$1,126
Prazosin Hcl63$938
Buspirone Hcl94$918
Oxcarbazepine21$823
Desmopressin Acetate13$809
Hydroxyzine Pamoate67$644

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Risperdal Consta$91$199,40871 claims
Lilly USA, LLCOlanzapine$122$1,12641 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,812 family providers in Ohio.

Other family in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →